Augmented mannose-binding lectin levels in primary membranous nephropathy: A pilot study

Area of Science:

• Nephrology
• Immunology
• Cardiovascular Medicine

Background:

• Primary membranous nephropathy (PMN) is linked to phospholipase A2 receptor (PLA2R) antibodies, potentially activating the mannose-binding lectin (MBL) cascade.
• Aberrant MBL activation may contribute to endothelial dysfunction and cardiovascular disease (CVD) risk in PMN patients.
• Research is needed to understand MBL's role in PMN's clinical activity and associated endothelial dysfunction.

Purpose of the Study:

• To investigate MBL levels in PMN patients.
• To assess the relationship between MBL levels, clinical activity, and endothelial dysfunction in PMN.
• To evaluate changes in MBL levels following immunosuppressive therapy.

Main Methods:

• MBL levels and flow-mediated vasodilation (FMD) were measured in 22 PMN patients and 22 healthy controls at baseline and after 6 months of therapy.
• FMD assessed endothelial function.
• Statistical analyses, including Spearman correlation, were used.

Main Results:

• PMN patients had significantly higher MBL levels than healthy controls (p < .01).
• MBL levels decreased significantly after immunosuppressive therapy (p = .04).
• Baseline MBL levels strongly correlated with FMD (ρ = 0.51, p = .01), indicating endothelial dysfunction.

Conclusions:

• The findings suggest MBL cascade activation in PMN.
• MBL levels are associated with endothelial dysfunction in PMN patients.
• MBL may serve as a potential biomarker for cardiovascular risk in PMN.